Find a Cancer Program  Log in to MyNetwork
Facebook  LinkedIn  Twitter  ACCC Youtube Channel

Search Drug Alphabetically

Generic Name Belantamab mafodotin-blmf
Brand Name Blenrep™
Payment Category Medicare Part B
Year Introduced 2020
Type of Drug BMCA-directed antibody and microtubule inhibitor conjugate
Manufacturer GlaxoSmithKline
Medical Affairs Questions (date verified) 877.475.6448
Coverage & Reimbursement Questions 877.423.6597
HCPCS Not yet assigned
Billing Unit Not yet assigned
Medicare Payment Limit (Effective January 1, 2021) Not yet determined

FDA-Approved Indication(s)

  • Indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. (8/06/20)

Approved Indication(s) with Orphan Drug Status None
ICD-10 Code(s) for Labeled Indication(s) Multiple myeloma [C90.x];
Name Strength Form Package Labeler NDC

Copyright © 2021 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949